One-Patient trial tests keytruda for rare ovarian cancer

NCT ID NCT05368207

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Because only one person took part, the results are very limited and cannot be generalized.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (Keytruda), a drug that helps the immune system fight cancer
What this could lead to: If it works, this could point toward a treatment option for a rare and aggressive ovarian cancer.
What could go wrong: This is a single-patient study with no control group, so results may not apply to others. The drug may not prevent cancer from returning and can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypercalcemic type ovarian small cell carcinoma ovarian cancer small cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER SMALL CELL CARCINOMA, HYPERCALCAEMIC TYPE

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.